MétaCan
← all works

Novel and emerging treatments for major depression

2022· review· en· 571 citations· W4311908682 on OpenAlex· 10.1016/s0140-6736(22)02080-3

Why is this work in the frame?

A frame that forgets how it found something cannot be audited. These are the routes that admitted this work.

Canadian funderA Canadian agency funded it. The work may carry no Canadian affiliation at all.

No Canadian affiliation. An affiliation-only frame — the usual design — would never have seen this work. It is one of the works that make the case for inverting the frame.

Machine scores (provisional)

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Opus teacher head0.135
GPT teacher head0.398
Teacher spread
0.263 · how far apart the two teachers sit on this one work
Validation status
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Abstract

No abstract. This is not a gap in this database — OpenAlex has none either. 23.3% of the frame is in this state, and the screen finds HALF as much metaresearch here, so the absence is a measured bias rather than a missing field.

The record

Venue
The Lancet
Topic
Treatment of Major Depression
Field
Medicine
Canadian institutions
Funders
National Institute of Mental HealthCanadian Institutes of Health ResearchNational Institute for Health and Care ResearchWellcome Trust
Keywords
Depression (economics)Psychological interventionMedicinePsychosocialClinical trialMajor depressive disorderPsychiatryIntensive care medicineMoodInternal medicine
Has abstract in OpenAlex
no